Your browser doesn't support javascript.
loading
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Rade, Michael; Grieb, Nora; Weiss, Ronald; Sia, Jaren; Fischer, Luise; Born, Patrick; Boldt, Andreas; Fricke, Stephan; Franz, Paul; Scolnick, Jonathan; Venkatraman, Lakshmi; Xu, Stacy; Kloetzer, Christina; Heyn, Simone; Kubasch, Anne Sophie; Baber, Ronny; Wang, Song Yau; Bach, Enrica; Hoffmann, Sandra; Ussmann, Jule; Schetschorke, Birthe; Hell, Saskia; Schwind, Sebastian; Metzeler, Klaus H; Herling, Marco; Jentzsch, Madlen; Franke, Georg-Nikolaus; Sack, Ulrich; Köhl, Ulrike; Platzbecker, Uwe; Reiche, Kristin; Vucinic, Vladan; Merz, Maximilian.
Afiliação
  • Rade M; Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
  • Grieb N; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Weiss R; Innovation Center Computer Assisted Surgery, University Hospital of Leipzig, Leipzig, Germany.
  • Sia J; Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
  • Fischer L; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
  • Born P; Singleron Biotechnologies, Cologne, Germany.
  • Boldt A; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Fricke S; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Franz P; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
  • Scolnick J; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
  • Venkatraman L; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
  • Xu S; Singleron Biotechnologies, Cologne, Germany.
  • Kloetzer C; Singleron Biotechnologies, Cologne, Germany.
  • Heyn S; Singleron Biotechnologies, Cologne, Germany.
  • Kubasch AS; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Baber R; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Wang SY; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Bach E; Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.
  • Hoffmann S; Leipzig Medical Biobank, University Leipzig, Leipzig, Germany.
  • Ussmann J; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Schetschorke B; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Hell S; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Schwind S; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Metzeler KH; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Herling M; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Jentzsch M; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Franke GN; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Sack U; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Köhl U; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Platzbecker U; Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
  • Reiche K; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
  • Vucinic V; Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
  • Merz M; Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
Nat Cancer ; 5(9): 1318-1333, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38641734
ABSTRACT
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos / Tratamento Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos / Tratamento Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha